Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma

doi:10.1590/1414-431X2024e13661

科研成果详情

题名	Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma
作者	Junhui Yang 1; Yunjie Zhang 1; Yifan Kong1; Jiawei Lin1; Guoqing Zhu2; Hao Zhang 3; Zhijie Yu1; Pixu Liu1; Jinglin Xia1,4
发表日期	2024
发表期刊	Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	Hepatocellular carcinoma Transarterial chemoembolization TACE refractoriness Inflammatory markers Predictive model
其他关键词	MANAGEMENT ; RECURRENCE ; PROGNOSIS
摘要	Transarterial chemoembolization (TACE) is an established therapeutic strategy for intermediate stage Barcelona Clinic Liver Cancer (BCLC) hepatocellular carcinoma (HCC). However, patients who are early refractory to TACE may not benefit from repeated TACE treatment. Our primary objective was to assess the diagnostic value of inflammatory markers in identifying early TACE refractory for patients with early (BCLC 0 and A) or intermediate (BCLC B) stage HCC. We retrospectively reviewed the HCC patients who underwent TACE as the initial treatment in two hospitals. Patients with early TACE refractoriness had significantly poorer median overall survival (OS) (16 vs 40 months, P<0.001) and progression-free survival (PFS) (7 vs 23 months, P<0.001) compared to TACE non-refractory patients. In the multivariate regression analysis, tumor size (P<0.001), bilobular invasion (P=0.007), high aspartate aminotransferase-to-platelet ratio index (APRI) (P=0.007), and high alpha fetoprotein (AFP) level (P=0.035) were independent risk factors for early TACE refractoriness. The predictive model showcasing these factors exhibited high ability proficiency, with an area under curve (AUC) of 0.833 (95%CI=0.774-0.892) in the training cohort, 0.750 (95%CI: 0.640-0.861) in the internal-validation cohort, and 0.733 (95%CI: 0.594-0.872) in the external-validation cohort. Calibration curve analysis revealed good agreement between the actual and predicted probabilities of early TACE refractoriness. Our preliminary study estimated the potential value of inflammatory markers in predicting early TACE refractoriness and provides a predictive model to assist in identifying patients who may not benefit from repeat TACE treatment.
资助项目	National Natural Science Foundation of China [81972233]; Major Scientific and Technological Innovation Project of Wenzhou Science and Technology Bureau [ZY2021 009]
出版者	ASSOC BRAS DIVULG CIENTIFICA
ISSN	0100-879X
EISSN	1414-431X
卷号	57
DOI	10.1590/1414-431X2024e13661
页数	13
WOS类目	Biology ; Medicine, Research & Experimental
WOS研究方向	Life Sciences & Biomedicine - Other Topics ; Research & Experimental Medicine
WOS记录号	WOS:001398659200001
收录类别	PUBMED ; SCIE
URL	查看原文
PubMed ID	39258671
通讯作者地址	[Xia, Jinglin]Wenzhou Med Univ, Zhejiang Key Lab Intelligent Canc Biomarker Disc, Affiliated Hosp 1, Wenzhou, Peoples R China. ; [Xia, Jinglin]Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China.
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/218917
专题	附属第一医院
作者单位	1.Zhejiang Key Laboratory of Intelligent Cancer Biomarker Discovery and Translation, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.; 2.Department of Interventional Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.; 3.Department of Gastroenterology, The Wenzhou Central Hospital, Wenzhou, Zhejiang Province, China.; 4.Liver Cancer Institute, Zhongshan Hospital of Fudan University, Shanghai, China.
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Junhui Yang,Yunjie Zhang,Yifan Kong,et al. Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma[J]. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,2024,57.
APA	Junhui Yang., Yunjie Zhang., Yifan Kong., Jiawei Lin., Guoqing Zhu., ... & Jinglin Xia. (2024). Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 57.
MLA	Junhui Yang,et al."Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma".Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 57(2024).